Preventive, founded by Lucas Harrington, seeks to research safe methods for heritable genome editing without rushing into practice. Harrington emphasizes the importance of rigorous research to potentially demonstrate the technology’s safety and benefits. The promise of editing embryos to eliminate genetic diseases raises ethical concerns and is met with skepticism from many in the scientific community, as most gene-editing specialists do not support such endeavors.
Despite the ongoing debate, Preventive is among several companies exploring this controversial technology. Harrington envisions a future where genetically edited individuals could remain free from diseases like heart disease or Alzheimer’s and pass these traits to their offspring. However, lack of significant backing from mainstream scientists and ongoing doubts about the practicality and ethics of heritable genome editing highlight the complexity of this venture. As discussions on the implications of this technology continue to evolve, Preventive aims to foster a responsible approach to such groundbreaking research.
👉 Pročitaj original: MIT Technology Review – AI
